Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now

3. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders: 92

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that manufactures, develops, markets, and sells biopharmaceutical products worldwide. It advances wellness, prevention, treatment, and cures in developing and emerging markets.

The company’s goal is to become a world-class oncology leader. It is already the third-largest biopharma company in oncology in the United States and plans to continue its progress for the rest of the decade.

On April 30, BMO Capital analyst Evan Seigerman maintained their bullish stance on Pfizer Inc. (NYSE:PFE), giving it a buy rating and suggesting it is well-positioned for future growth. The analyst reasoned that the company’s recent financial performance reflects strong operational efficiency that could potentially result in improved profitability. This especially includes Pfizer Inc.’s (NYSE:PFE) ability to surpass expectations on cost savings.

Management is also committed to maintaining its dividend and strategic capital allocation, which reflects confidence in its future prospects and financial stability. Pfizer Inc. (NYSE:PFE) is proactively navigating the challenges of current economic and political landscape, which favorably position it compared to its peers, according to the analyst.